Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
influenza virus vaccine, quadrivalent, split virus
- Development stage
- Phase 3
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Quadrivalent split influenza virus vaccine is an inactivated vaccine prepared from influenza viruses propagated in embryonated hens' eggs. It contains four influenza virus strains: two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata). The viruses are inactivated with ultraviolet light treatment followed by formaldehyde treatment, purified by centrifugation, and disrupted with sodium deoxycholate. It is administered via intramuscular injection for the prevention of seasonal influenza.
- Brand names
- FluLaval QuadrivalentFluzone Quadrivalent
- Other names
- quadrivalent split influenza virus vaccineIIV4IIV-4IIV 4Influenza Vaccine, Quadrivalent
Beyond the preview
Go deeper on influenza virus vaccine, quadrivalent, split virus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on influenza virus vaccine, quadrivalent, split virus.